ACADIA Pharmaceuticals Inc. (ACAD) Financials
ACAD Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 749.0 million | 317.2 million |
2023-09-30 | 632.5 million | 270.4 million |
2023-06-30 | 642.8 million | 247.0 million |
2023-03-31 | 655.3 million | 281.0 million |
ACAD Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 85.4 million | 18.0 million |
2023-09-30 | -59.0 million | 18.5 million |
2023-06-30 | -31.8 million | 15.2 million |
2023-03-31 | -17.9 million | 14.7 million |
ACAD Net Income
No data available :(
ACAD Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 438.9 million | - | 57.2 million |
2023-09-30 | 345.9 million | - | 48.1 million |
2023-06-30 | 375.4 million | - | 49.8 million |
2023-03-31 | 402.9 million | - | 51.4 million |
ACAD Shares Outstanding
ACAD Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 66.7 million | 111.5 million | - |
2023-09-30 | 50000 | 157.0 million | 97.9 million | - |
2023-06-30 | 40.0 million | 58.8 million | 96.0 million | - |
2023-03-31 | 69.6 million | 69.1 million | 101.2 million | - |
ACAD Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 231.0 million | 17.9 million |
2023-09-30 | 211.7 million | 14.6 million |
2023-06-30 | 165.2 million | 7.5 million |
2023-03-31 | 118.5 million | 1.7 million |
ACAD
Price: $17.05
52 week price:
Earnings Per Share: -0.37 USD
P/E Ratio: -27.67
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.4 million
Ebitda: -65.6 millionMarket Capitalization: 2.9 billion